Dr Jos van den Berg reviews the REALDES and REALISR multicenter studies out of Japan, which compared the Zilver PTX and Eluvia drug-eluting stents through 3 years.
Dr Jos van den Berg reviews the REALDES and REALISR multicenter studies out of Japan, which compared the Zilver PTX and Eluvia drug-eluting stents through 3 years.
The FLEX Vessel Prep (FLEX VP) System (Flex Vascular) represents a different concept of lesion preparation. Rather than relying primarily on high radial balloon pressure or tissue removal, FLEX VP uses controlled longitudinal microincisions...
The FLEX Vessel Prep (FLEX VP) System (Flex Vascular) represents a different concept of lesion preparation. Rather than relying primarily on high radial balloon pressure or tissue removal, FLEX VP uses controlled longitudinal microincisions...
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI; Marianne Brodmann, MD; Keith Sterling, MD
Drs Secemsky, Brodmann, and Sterling review the evolution of the paclitaxel discussion, examine contemporary evidence from clinical trials and real-world studies.
Drs Secemsky, Brodmann, and Sterling review the evolution of the paclitaxel discussion, examine contemporary evidence from clinical trials and real-world studies.
This case report discusses a 67-year-old man with lifestyle-limiting claudication and a resting left ankle-brachial index of 0.52 secondary to a 60-mm, moderately-to-severely calcified superficial femoral artery CTO.
This case report discusses a 67-year-old man with lifestyle-limiting claudication and a resting left ankle-brachial index of 0.52 secondary to a 60-mm, moderately-to-severely calcified superficial femoral artery CTO.
This case report describes the use of the DETOUR system to successfully treat a dense calcific TASC D lesion with associated tissue loss and ultimate limb salvage.
This case report describes the use of the DETOUR system to successfully treat a dense calcific TASC D lesion with associated tissue loss and ultimate limb salvage.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Zola N'Dandu, MD, discusses one of the presentations he gave at the 2026 Amputation Prevention Symposium on what is needed to successfully perform deep venous arterialization.
Zola N'Dandu, MD, discusses one of the presentations he gave at the 2026 Amputation Prevention Symposium on what is needed to successfully perform deep venous arterialization.
Dr Mike Watts examines an important question surrounding DVA: not simply whether the procedure can prevent amputation in patients with no-option CLTI, but how the economics of care delivery influence where and how it can be successfully...
Dr Mike Watts examines an important question surrounding DVA: not simply whether the procedure can prevent amputation in patients with no-option CLTI, but how the economics of care delivery influence where and how it can be successfully...
Yana Etkin, MD, presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD, presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Mike Watts examines an important question surrounding DVA: not simply whether the procedure can prevent amputation in patients with no-option CLTI, but how the economics of care delivery influence where and how it can be successfully...
Dr Mike Watts examines an important question surrounding DVA: not simply whether the procedure can prevent amputation in patients with no-option CLTI, but how the economics of care delivery influence where and how it can be successfully...
Yana Etkin, MD, presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Yana Etkin, MD, presented an in-depth review of strategies for identifying and managing failing DVA, emphasizing that long-term success depends not only on creating the DVA circuit but also on maintaining its patency through vigilant...
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Alik Farber, MD, MBA, presented the latest 4-year findings from the landmark BEST-CLI trial. He challenged attendees to move beyond the long-standing debate of surgery vs endovascular intervention and instead embrace an evidence-based,...
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
Dr Eric Secemsky presented a review of the evidence supporting contemporary medical management for patients with PAD and CLTI, emphasizing that pharmacologic therapy remains an essential pillar of reducing cardiovascular events.
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
During a Thursday afternoon session at the Amputation Prevention Symposium 2026, Ralf Langhoff, MD, asked attendees to reconsider when retrograde access should be used for chronic total occlusion (CTO) interventions.
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Ramon L. Varcoe presented an update on bioresorbable BTK technology, highlighting the growing body of evidence supporting the Esprit™ BTK drug-eluting resorbable scaffold (Abbott Cardiovascular) for the treatment of CLTI.
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
Dr Pradeep K. Nair presented the clinical rationale, engineering design, pivotal clinical data, and early real-world experience with the Santreva-ATK Endovascular Revascularization Catheter (AngioSafe).
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
This presentation examined the evolving evidence supporting the SELUTION SLR sirolimus drug-eluting balloon (Cordis) as a treatment strategy for femoropopliteal and BTK PAD, with particular emphasis on complex CLTI.
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Tim Wittig, MD, presents the primary outcomes from the MOTIV BTK Trial, which evaluated the safety and efficacy of the sirolimus-eluting bioresorbable scaffold MOTIV BTK.
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents a case-based discussion on how advanced vascular imaging should guide the decision between an endovascular-first or surgical bypass-first approach for patients with PAD and CLTI.
Dr Eric Scott presents presents...
08/05/2026
Vascular Disease Management
About Us
Vascular Disease Management™ (VDM), the official media partner of the International Symposium on Endovascular Therapy (ISET) and the Amputation Prevention Symposium (AMP), educates readers on the latest advancements in endovascular treatment strategies.
Learn more about ISET and AMP and register for the events here:
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
Tampa, Florida – Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated...
Tampa, Florida – Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
JUNE 16, 2025 – HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the Spur® Peripheral Retrievable Stent System to treat chronic...
JUNE 16, 2025 – HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the Spur® Peripheral Retrievable Stent System to treat chronic...
NEW ORLEANS, LA, JUNE 6, 2025 – A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of...
NEW ORLEANS, LA, JUNE 6, 2025 – A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of...
May 24, 2024 – Lafayette, LA – Cardiovascular Institute of the South (CIS) is the first in the world to use the 200-cm RANGER Drug-Coated Balloon to treat peripheral artery disease (PAD) in the legs. CIS interventional cardiologist Dr....
May 24, 2024 – Lafayette, LA – Cardiovascular Institute of the South (CIS) is the first in the world to use the 200-cm RANGER Drug-Coated Balloon to treat peripheral artery disease (PAD) in the legs. CIS interventional cardiologist Dr....
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR)3-6 and to date, it has been used to treat more than 100,000 patients7 in the United...
The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR)3-6 and to date, it has been used to treat more than 100,000 patients7 in the United...
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions;data show the device achieved high closure rates of...
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions;data show the device achieved high closure rates of...
The trial is funded by the National Institute of Neurological Disorders and Stroke (NINDS) and is open to patients diagnosed within the last six months with an ischemic stroke or high-risk transient ischemic attack (TIA).
The trial is funded by the National Institute of Neurological Disorders and Stroke (NINDS) and is open to patients diagnosed within the last six months with an ischemic stroke or high-risk transient ischemic attack (TIA).
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the...
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the...
ALAMEDA, Calif. -- Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™)...
ALAMEDA, Calif. -- Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™)...
The Vertex system leverages the company’s proprietary Transforming Fixation (TFX) platform technology, a single catheter designed to navigate flexibly through the right heart and stabilize on-demand in the pulmonary arteries for precise,...
The Vertex system leverages the company’s proprietary Transforming Fixation (TFX) platform technology, a single catheter designed to navigate flexibly through the right heart and stabilize on-demand in the pulmonary arteries for precise,...
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
